Impact of a Mindfulness-Based Stress Reduction Program on Depressive and Anxiety Symptomatology, Stress and Cortisol Levels and the Quality of Life in Premenopausal Patients with Polycystic Ovary Syndrome

Program: Abstracts - Orals, Poster Preview Presentations, and Posters
Session: MON 0649-0671-Hypothalamic-Pituitary-Adrenal Axis - CAH, AI & Cushing's
Clinical
Monday, June 23, 2014: 1:00 PM-3:00 PM
Hall F (McCormick Place West Building)

Poster Board MON-0656
Charikleia Stefanaki1, Sarantis Livadas, MD, PhD2, Anna Kandaraki, M.Sc.3, Flora Bacopoulou, M.D., Ph.D.4, Athanasios Karachalios1, Evanthia Diamanti-Kandarakis, M.D., Ph.D.3 and George P. Chrousos, MD, PhD5
1Athens University Medical School, Athens, Greece, 2Unit of Endocrinology, Metabolism and Diabetes, Athina, Greece, 3Athens University Medical School, Athens, Greece, Athens, Greece, 4University of Athens, Children's Hospital 'Aghia Sophia', Athens, Greece, 5University of Athens School of Medicine, Athens, Greece
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders in women, with a prevalence of about 7%. PCOS is associated with high incidence of anxiety and depressive symptomatology, which indicates stress system dysfunction in these patients. This reduces their quality of life and accelerates the development of chronic non-communicable disorders, such as obesity, cardiometabolic diseases and cancer. Mindfulness-based Stress Reduction (MBSR) programs promote stress alleviation by producing a relaxation response. In this single-masked, randomized, controlled trial, we used an 8-wk MBSR program, accompanied by a weekly 30-min session with the principal investigator. Twenty-three PCOS patients of reproductive age and fifteen controls were randomly allocated and administered the DASS21, PSS-14, PCOSQ, Daily Life and General Life Satisfaction Questionnaires both before and after the intervention. At the same time points they also provided three serial samples for salivary cortisol measurements. Patients in the intervention group were also given the Credibility/Expectancy Questionnaire at the day of enrollment, to look for a possible placebo effect in the outcome measures and to evaluate expectancy for change and treatment credibility. Post-intervention between group results revealed statistically significant differences in depressive symptoms (p = 0.011) and stress levels (p = 0.025). There were statistically significant reductions in stress-associated (95% C.I.: 4.38 – 9.7, p = 0.000), anxiety (95% C.I.: 1.74 – 5.91, p = 0.001) and depressive (95% C.I.: 1.66 – 6.33, p = 0.002) symptoms, along with a significant increase in Life Satisfaction and Quality of Life scores in the intervention group only. Lastly, cortisol AUCg in the intervention group, demonstrated a statistically significant reduction (p = 0.037). According to our results, there was no impact of the study on the credibility and/or expectancy, and, hence, no placebo effect. The data suggest that MBSR in PCOS patients leads to significant reductions in stress-associated, anxiety and depressive symptoms, as well as salivary cortisol, and ameliorates their quality of life. These findings also imply that relaxation techniques might be useful alternative therapies for other non-PCOS hyperandrogenic disorders.

Nothing to Disclose: CS, SL, AK, FB, AK, ED, GPC

*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting